Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was up 4.3% during mid-day trading on Wednesday . The company traded as high as $0.24 and last traded at $0.24, approximately 14,910 shares traded hands during mid-day trading. A decline of 99% from the average daily volume of 1,060,599 shares. The stock had previously closed at $0.23.

A number of equities analysts have recently weighed in on ATNM shares. Zacks Investment Research downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 4th. Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 4th. Finally, William Blair started coverage on Actinium Pharmaceuticals in a research report on Thursday, August 8th. They set an “outperform” rating for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.56.

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Sio Capital Management LLC lifted its position in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 1,352.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,935,250 shares of the biotechnology company’s stock after purchasing an additional 4,595,454 shares during the quarter. Sio Capital Management LLC owned approximately 3.05% of Actinium Pharmaceuticals worth $1,214,000 as of its most recent filing with the Securities and Exchange Commission.

Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Further Reading: Rule of 72

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.